Key Updates
Berkshire Hathaway shares declined 2.01% to $723,245 since the January 14 report, extending YTD losses to 4.18% as the market digests two significant portfolio developments under new CEO Greg Abel. The most material news is Berkshire's potential exit from its entire 27% Kraft Heinz stake (325.4 million shares), marking Abel's first major divestiture decision and representing a definitive end to one of Warren Buffett's rare acknowledged investment mistakes. Concurrently, Berkshire completed the $9.7 billion OxyChem acquisition on January 2, adding a top-three U.S. chemical producer to its industrial portfolio. These opposing capital allocation moves—divesting a struggling consumer staples position while deploying cash into industrial chemicals—signal Abel's willingness to reshape the portfolio more aggressively than anticipated during the leadership transition.
Current Trend
Berkshire shares have entered a corrective phase, declining across all short-term timeframes: down 0.58% (1-day), 2.57% (5-day), 3.57% (1-month), and 4.18% YTD. The stock has now retraced most of its 6-month gain of 1.72%, indicating consolidation following the CEO transition. At $723,245, shares are testing support levels established in early January after the golden cross formation noted in the previous report (50-day MA crossing above 200-day MA at approximately $498 for Class B shares). The consistent negative momentum across multiple timeframes suggests investor uncertainty about Abel's capital allocation strategy, particularly given the $381.7 billion cash position and the mixed signals from simultaneous acquisition activity and major divestiture plans. The stock continues to underperform broader market indices, extending the trend identified in the December and January reports.
Investment Thesis
The core investment thesis centers on Berkshire's ability to maintain its operational excellence and capital allocation discipline during the post-Buffett transition under Greg Abel's leadership. With a diversified conglomerate structure spanning insurance (GEICO), transportation (BNSF Railway), energy, manufacturing, and now chemicals (OxyChem), Berkshire offers defensive characteristics combined with substantial deployment optionality through its record $381.7 billion cash position. The thesis assumes Abel will leverage this liquidity for value-accretive acquisitions while maintaining the decentralized operating model that has driven consistent performance. However, the investment case faces near-term headwinds from governance uncertainty as Buffett's $148 billion stake will be gradually donated over the next decade, potentially diluting voting control and exposing the company to shareholder activism for the first time in its history. The thesis requires Abel to demonstrate strategic clarity on capital deployment, particularly given Berkshire's recent underperformance versus the S&P 500 and reduced buyback activity despite trading below historical premium valuations.
Thesis Status
The thesis is experiencing meaningful stress as new information reveals both progress and concerns. On the positive side, the completed OxyChem acquisition demonstrates Abel's willingness to deploy capital into industrial assets with essential product exposure (water treatment, pharmaceuticals, construction), validating the deployment optionality component of the thesis. However, the potential Kraft Heinz exit introduces significant uncertainty. While divesting a position down 60% since the 2015 merger represents prudent portfolio management, the timing—immediately after Abel assumed the CEO role—raises questions about whether additional portfolio restructuring is forthcoming. The market's negative reaction (4.18% YTD decline) suggests investors are discounting the stock for transition uncertainty rather than rewarding decisive action. The governance concerns outlined in the CNBC analysis of Buffett's wealth donation plan represent a new structural risk not previously incorporated into the thesis, as the gradual dilution of voting control could fundamentally alter Berkshire's governance model within the next decade.
Key Drivers
Three primary drivers are shaping near-term performance. First, portfolio restructuring under Abel has emerged as the dominant narrative, with the Kraft Heinz divestiture filing signaling potential for additional position exits beyond the previously disclosed Apple and Bank of America reductions. This represents Abel's first signature capital allocation decision and will set the tone for his tenure. Second, capital deployment strategy remains critical, as evidenced by the $9.7 billion OxyChem acquisition, which deploys less than 3% of the cash stockpile but establishes Abel's acquisition preferences toward industrial businesses with essential product exposure. Third, governance evolution is becoming a longer-term factor, with Buffett's pledge to donate 99% of his $148 billion stake within 10 years potentially exposing Berkshire to activist pressure for the first time, particularly regarding the massive cash position and buyback strategy. These drivers are interconnected: Abel's capital allocation decisions will be scrutinized more intensely as Buffett's voting control diminishes, creating pressure for clearer strategic communication.
Technical Analysis
Berkshire shares are exhibiting bearish short-term momentum despite the bullish golden cross formation identified at the start of Abel's tenure. The stock has declined consistently across all measured timeframes, with the 1-month decline of 3.57% and YTD loss of 4.18% indicating persistent selling pressure. The current price of $723,245 represents a test of support levels established in early January following the CEO transition. The Class B shares' golden cross pattern (50-day MA at $498.18 crossing above 200-day MA at $497.92) historically precedes average gains of 30% based on 14 prior occurrences over 25 years, but the pattern's predictive value may be diminished by the unprecedented leadership transition. Volume and volatility patterns suggest institutional repositioning rather than broad-based selling, consistent with investors reassessing position sizing during the transition period. Key resistance now sits at the $750,000 level (previous support from December), while support exists around $700,000. The technical setup remains constructive on longer timeframes (6-month gain of 1.72%) but requires stabilization in the near term to validate the golden cross signal.
Bull Case
- Strategic portfolio optimization through Kraft Heinz exit: The potential divestiture of the entire 27% Kraft Heinz stake demonstrates Abel's willingness to exit underperforming positions decisively, with the stock down 60% since the 2015 merger. This capital reallocation away from a struggling consumer staples business could redeploy proceeds into higher-return opportunities, improving portfolio quality and signaling disciplined capital stewardship under new leadership.
- Accretive industrial acquisition expanding essential products exposure: The completed $9.7 billion OxyChem acquisition adds a top-three U.S. producer of essential chemicals serving water treatment, pharmaceuticals, healthcare, and construction sectors. This defensive, cash-generative business aligns with Berkshire's operating model and provides inflation-protected revenue streams through essential industrial inputs, demonstrating Abel's acquisition discipline.
- Record capital deployment capacity with $381.7 billion cash position: Berkshire's record cash holdings as of September 30 provide unprecedented optionality for Abel to execute transformative acquisitions or accelerate buybacks. Investment strategists suggest this cash accumulation was intentional to enable significant 2026 investments, potentially in energy or defense sectors, positioning the company for value-accretive deployment.
- Historical golden cross pattern with 30% average subsequent gains: The bullish golden cross formation in early January, with the 50-day MA crossing above the 200-day MA, has historically preceded average gains of approximately 30% based on 14 occurrences over the past 25 years. This technical setup suggests potential for significant appreciation as the pattern plays out over the coming months.
- Succession discount creating valuation opportunity: Investment strategists characterize the current valuation as a "succession discount" with the stock trading below its potential value as investors await Abel's performance. As Abel demonstrates operational competence and strategic clarity, this discount should compress, particularly given Berkshire's 34% year-over-year operating income growth to $13.5 billion in Q3 and Buffett's endorsement that the company has "the best odds of any company for lasting a century."
Bear Case
- Governance vulnerability from Buffett's stake dilution exposing company to activism: Buffett's plan to donate 99% of his $148 billion stake within 10 years will gradually dilute voting control, potentially exposing Berkshire to shareholder activism for the first time in six decades. As voting power disperses among Buffett's heirs, pressure will mount on Abel for clearer capital allocation strategies, particularly regarding the massive cash position and limited buyback activity, fundamentally altering the governance structure that has protected management autonomy.
- Immediate market rejection of major portfolio decision signaling execution risk: The Kraft Heinz divestiture announcement triggered a 4.9% after-hours decline in Kraft Heinz shares and contributed to Berkshire's own weakness, demonstrating market skepticism about Abel's timing and communication of major decisions. The fact that Abel and Buffett had publicly opposed the Kraft Heinz split as "costly and disruptive" yet are now exiting entirely raises concerns about strategic consistency and decision-making processes under new leadership.
- Persistent underperformance versus S&P 500 continuing into new leadership era: Berkshire gained 10.9% in 2025, underperforming the S&P 500's 16.4% rise, and the YTD decline of 4.18% extends this underperformance into 2026. The stock has declined 7.6% since Buffett's retirement announcement in May, indicating the market is discounting the shares for transition risk rather than rewarding the operational stability demonstrated by record cash generation and operating income growth.
- Capital deployment challenges with $381.7 billion cash generating minimal returns: Despite record liquidity, Berkshire has been reducing major positions in Apple and Bank of America while conducting limited buyback activity, suggesting difficulty finding attractive deployment opportunities at scale. The OxyChem acquisition deployed less than 3% of available cash, and with the equity portfolio totaling $283.2 billion as of September 30, the company faces mounting pressure to demonstrate how it will generate acceptable returns on the massive cash drag in a competitive M&A environment.
- Leadership transition uncertainty with Abel's unproven track record in public CEO role: While Buffett endorsed Abel as "a great manager, a tireless worker and an honest communicator," Abel has never served as a public company CEO and faces investor concerns about managing the sprawling $1 trillion enterprise and maintaining the premium valuation Berkshire commanded under Buffett. The immediate portfolio restructuring decisions and market's negative reaction suggest Abel's leadership style and strategic priorities differ materially from Buffett's approach, introducing execution risk during a critical transition period.